Background: Neoadjuvant chemotherapy is the systemic chemotherapy before the start of local chemotherapy or radiotherapy. At present, neoadjuvant chemotherapy in the high-risk phase II (AJCC TNM stage II period, including T3N0M0 and T4N0M0) treatment of colon cancer reported less. The authors discussed the efficacy and safety of neoadjuvant chemotherapy in 24 patients with high-risk stage II colorectal cancer. Method: Forty-eight patients with stage II colorectal cancer were randomly divided into experimental group and control group, the postoperative complications, the side effects of chemotherapy drugs and the effect of chemotherapy drugs on the tumor were observed. The quality of life, survival time and tumor recurrence or metastasis was compared between the two groups. Result: 1) The incidence of complications in the neoadjuvant chemotherapy group was 20.8%, the incidence of adjuvant chemotherapy was 25%, and the overall complication rate was 22.9%. P values were greater than 0.05. 2) Through the comparison of the two groups of toxic and side effects, after SPASS software analysis, obtained P > 0.05, the two groups were not statistically significant. 3) After 3 -4 courses of preoperative chemotherapy, CR (complete remission) and PD (disease progression) patients were 0 cases, PR (partial remission) was 11 (45.8%), NC/SD (no change) was 13 (54.2%). 4) Through the comparison of the quality of life of the two groups of patients, from the function, symptoms and the overall situation to statistics, P value < 0.05, This comparison makes sense. 5) The 1-year survival rate was 100% (24/24) in the control group, with a 3-year survival rate of 92% (22/24) and a 5-year survival rate of 75% (9/12). All survival rates in the experimental group were 100% (24/24). 6) There were no recurrence or metastasis cases in the neoadjuvant chemotherapy group, and 2 cases of recurrence and 1 case of metastasis in the adjuvant chemotherapy group were compared with the recurrence or metastasis after tumor operation. The chi-square test is not How to cite this paper: Wang,
Introduction
Colon cancer is a common gastrointestinal cancer, and it is one of the fastest rising tumor incidences in China. Early tumor generally has no obvious symp- 
Materials and Methods

Clinical Data
Retrospectively 2012-01-01 to 2014-07-01 in Xiaogan City Center for general surgery high-risk stage of colon cancer patients in 48 cases, including 27 males and 21 females, aged 45 -70 years, mean age 64.5 years old. Were divided into two groups, the experimental group was neoadjuvant chemotherapy group, the 
Surgical Program
All colon cancer surgery by the same chief physician in general anesthesia under the laparoscopic radical resection of colon cancer, intraoperative strict implementation of the principle of aseptic and tumor-free operation, Resection and resection methods follow the guidelines for surgical procedures, tumor mass after removal of the disease were sent to the disease. 
Chemotherapy
Efficacy Evaluation and Follow-Up
To observe the postoperative complications of the two groups of patients, the side effects of chemotherapy drugs and the role of chemotherapy drugs on the tumor, the quality of life, survival time and tumor recurrence or metastasis were compared between the two groups. The first three indicators are available during hospitalization, and the latter three indicators can be obtained by telephone,
WeChat or outpatient review.
Data Processing
Using SPASS16.0 software package, Measurement data using the mean and standard deviation and T test, Counting data usage rate and the use of chisquare test, using the probability P value for statistical inference, P < 0.05 was statistically significant.
Among them, the quality of life assessment of patients use EORTC QLQ-C30 
Result
By comparing the intraoperative and postoperative complications of the two groups of patients, the experimental group (neoadjuvant chemotherapy group) postoperative pneumonia in 3 cases (12.5%), intestinal obstruction in 1 case case (4.1%). The incidence of complications in the neoadjuvant chemotherapy group was 20.8%, the incidence of adjuvant chemotherapy was 25%, and the overall complication rate was 22.9%. The chi-square test P value is greater than 0.05, can be concluded that the experimental group no significant increase in postoperative complications, is relatively safe. See Table 2 .
By comparing the side effects of two groups of chemotherapy drugs, after analysis, P > 0.05, showing no significant difference between the two groups of chemotherapy drugs side effects, neoadjuvant chemotherapy is a safe solution, patients can tolerate the treatment options. See Table 3 CR (complete remission) and PD (disease progression) were 0 patients with preoperative chemotherapy, and PR (partial remission) were compared with those of abdominal CT when abdominal CT was compared with preoperative examination. (45.8%), NC/SD (no change) was 13 cases (54.2%), it can be seen that preoperative chemotherapy has a significant effect on some patients. See Table 4 . Table 5 .
Compare the survival time of the two groups of patients, the 1-year survival rate was 100% (24/24), the 1-year survival rate was 100% (24/24), the 3-year survival rate was 92% (22/24), the 5-year survival rate For 75% (9/12), It can be seen that the survival rate of the experimental group was significantly higher in patients with stage II colorectal cancer. See Table 6 .
Through the comparison of recurrence or metastasis after tumor surgery, Neoadjuvant chemotherapy group without recurrence or metastasis cases, adjuvant chemotherapy group can be seen in 2 cases of recurrence, 1 case of metastasis. The chi-square test, no statistical significance, may be due to too little sample, no obvious conclusion. See Table 7 . 
Discussion
In China, the incidence and mortality of colorectal cancer are located at the third and fourth of the malignant tumors, respectively, and the incidence of colorectal cancer in China is increasing at an annual rate of twice the world average.
High-risk groups of colon cancer include: to reduce the iatrogenic planting [4] . Journal of Cancer Therapy
Like Li et al. believe that neoadjuvant chemotherapy within two weeks after the chance of anastomotic fistula, three weeks after the end of chemotherapy more safe operation [5] . Therefore, for the sake of conservatism, this study is recommended for patients with neoadjuvant chemotherapy after about four weeks of surgical treatment, the same, adjuvant chemotherapy group, is also around four weeks after adjuvant chemotherapy. On the best timing of adjuvant chemotherapy, the United Kingdom SAFFA test, including a number of studies have shown that 8 weeks after adjuvant chemotherapy in patients with colorectal cancer survival rate was no significant difference with the control group, postoperative adjuvant chemotherapy later, its survival The worse the condition, and chemotherapy time for each extension of 4 weeks, OS decreased by 14%.The time to start chemotherapy is affected by preoperative albumin levels, lymphatic metastases, and laparoscopic surgery [6] .
In this study, we investigated the effect of neoadjuvant chemotherapy on highrisk stage II colorectal cancer:
1) By comparing the intraoperative and postoperative complications of the two groups, P value was greater than 0.05, can be obtained in the experimental group postoperative complications No significant increase, is relatively safe.
2) Compared with the two groups of toxic and side effects, after SPASS software analysis, obtained P > 0.05, the two groups were not statistically significant, the experimental group and the control group did not find significant differences. Visible neoadjuvant chemotherapy is a safer, patient tolerable treatment regimen.
3) through the abdomen of the abdomen CT and preoperative review of abdominal CT were compared, after 3 -4 courses of preoperative chemotherapy, CR (complete remission) and PD (disease progression) patients were 0 cases, PR (partial remission) was 11 cases (45.8%) and NC/SD (no change) were 13 cases (54.2%). It was found that preoperative chemotherapy had significant effect on some patients.
4) The quality of life in the experimental group was significantly higher than that in the control group (P < 0.05). The quality of life in the experimental group was significantly higher than that in the control group (P < 0.05). The quality of life was significantly higher than that of the control group Patients benefit from neoadjuvant chemotherapy. Neoadjuvant chemotherapy improves clinical efficacy.
5) The survival rate of the two groups was 100% (24/24), the 1-year survival rate was 100% (24/24), the 3-year survival rate was 92% (22/24). The 5-year survival rate was 75% (9/12). It was found that the survival rate of patients with high-risk stage II colon cancer was significantly improved.
6) There were no recurrence or metastasis cases in the neoadjuvant chemotherapy group, and 2 cases of recurrence and 1 case of metastasis in the adjuvant chemotherapy group were compared with the recurrence or metastasis after tumor operation. The chi-square test, no statistical significance, may be due to too This article also has more defects, such as less sample size, can not evaluate the impact of chemotherapy on surgery, adjuvant chemotherapy evidence needs to be further improved and so on.
Conclusion
In summary, neoadjuvant chemotherapy plays a role in patients with high-risk second-stage colon cancer, and the experimental group benefited significantly, especially in quality of life and survival time. At the same time, neoadjuvant chemotherapy is also a safe treatment, so as to play a certain clinical guidance.
